Cilastatin

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

肾脱氢肽酶-I 和白三烯 D4 二肽酶抑制剂。

A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, imipenem, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 to leukotriene E4.(In Vitro):Cilastatin (200 μg/mL; 24 hours; RPTECs) treatment protects against Vancomycin-induced proximal tubule apoptosis and increases cell viability, without compromising the antimicrobial effect of Vancomycin.(In Vivo):In a mouse model (female mice, strain CD-1, 20 g) of systemic infection, Imipenem plus Cilastatin can protect mice from S. aureus, E. coli, and P. aeruginosa infection.

Cilastatin (200 μg/mL; 24 hours; RPTECs) treatment protects against Vancomycin-induced proximal tubule apoptosis and increases cell viability, without compromising the antimicrobial effect of Vancomycin. Apoptosis Analysis Cell Line:Renal proximal tubular epithelial cells (RPTECs) Concentration:200 μg/mL Incubation Time:24 hours Result:Significantly ameliorated Vancomycin-induced nuclear apoptosis.

In a mouse model (female mice, strain CD-1, 20 g) of systemic infection, Imipenem plus Cilastatin can protect mice from S. aureus, E. coli, and P. aeruginosa infection.

——

Proteasome/Ubiquitin

Proteasome

Dipeptidase 1

——

——

82009-34-5

358.45

C16H26N2O5S

>98% (HPLC)

DMSO: 10 mM

CC1(C[C@H]1C(=O)N/C(=C\CCCCSC[C@H](C(=O)O)N)/C(=O)O)C

——

(-20℃)

With Ice Pack

≥ 2 years